Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | UGCG | Q16739 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | HNF4A | P41235 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22646765 | 0.88 | ALDH1A1 (0.52) | ALDH1A1MRGPRX1CYP1A2CYP2C9KDM4E | |
| SCHEMBL20060388 | 0.88 | MAOB (0.47) | ALDH1A1MRGPRX1MAOBMAOAKDM4E | |
| SCHEMBL7345021 | 0.86 | KDM4E (0.48) | ALDH1A1MRGPRX1CYP1A2CYP2C9KDM4E | |
| SCHEMBL25247535 | 0.85 | FFAR4 (0.56) | ALDH1A1MRGPRX1CYP1A2CYP2C9KDM4E | |
| SCHEMBL28417947 | 0.83 | KDM4E (0.46) | ALDH1A1MRGPRX1CYP1A2CYP2C9KDM4E | |
| SCHEMBL17859344 | 0.82 | LMNA (0.60) | ALDH1A1CYP1A2CYP2C9KDM4EMAPT | |
| SCHEMBL4271221 | 0.82 | CYP3A4 (0.61) | ALDH1A1MRGPRX1CYP1A2MAOBMAOA | |
| SCHEMBL30628273 | 0.82 | CYP3A4 (0.61) | ALDH1A1MRGPRX1CYP1A2MAOBMAOA | |
| SCHEMBL19524218 | 0.80 | SCN8A (0.62) | ALDH1A1CYP1A2CYP2C9KDM4EMAPT | |
| SCHEMBL17420753 | 0.80 | MRGPRX1 (0.45) | ALDH1A1MRGPRX1CYP1A2CYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3166937-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-08-09 | — | — | US | disclosed |
| US-9968596-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-01-25 | — | — | US | disclosed |
| US-9808451-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3166937-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | Celgene Corporation (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2017-01-12 | — | — | US | disclosed |
| US-9499514-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| US-6090805-A | Tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5968938-A | Piperazine oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | ALDH1A1 247/4885MRGPRX1 3506/4885CYP1A2 2288/4885 |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | ALDH1A1 247/4885MRGPRX1 3506/4885CYP1A2 2288/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | ALDH1A1 247/4885MRGPRX1 3506/4885CYP1A2 2288/4885 |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | ALDH1A1 247/4885MRGPRX1 3506/4885CYP1A2 2288/4885 |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | ALDH1A1 247/4885MRGPRX1 3506/4885CYP1A2 2288/4885 |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | ALDH1A1 247/4885MRGPRX1 3506/4885CYP1A2 2288/4885 |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | ALDH1A1 247/4885MRGPRX1 3506/4885CYP1A2 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.